PDCD1 and susceptibility to pneumonia measurement: In addition, the MACE group had more concurrent side effects, such as PD-1-mediated pneumonia [7/24 (29.2%) vs. 1/110 (0.9%)], hepatitis [3/24 (12.5%) vs. 3/110 (2.7%)], myositis [4/24 (16.7%) vs. 3/110 (2.7%)], and thyroid dysfunction [5/24 (20.8%) vs. 16/110 (14.5%)].